BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
Cerilliant
Chubb
Daiichi Sankyo
Covington
Cipla
AstraZeneca
UBS
Cantor Fitzgerald

Generated: January 22, 2018

DrugPatentWatch Database Preview

XHANCE Drug Profile

« Back to Dashboard

Which patents cover Xhance, and when can generic versions of Xhance launch?

Xhance is a drug marketed by Optnose Us and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and sixty-three patent family members in twenty-six countries.

The generic ingredient in XHANCE is fluticasone propionate. There are twenty-six drug master file entries for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
Summary for XHANCE
International Patents:163
US Patents:9
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:XHANCE at DailyMed
Drug patent expirations by year for XHANCE

US Patents and Regulatory Information for XHANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Optnose Us XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Optnose Us XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Optnose Us XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Optnose Us XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Optnose Us XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Optnose Us XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Optnose Us XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Optnose Us XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Optnose Us XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Optnose Us XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for XHANCE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,347,201 Nasal delivery devices ➤ Subscribe
8,596,278 Nasal devices ➤ Subscribe
8,511,303 Nasal delivery devices ➤ Subscribe
9,205,208 Nasal devices ➤ Subscribe
8,555,877 Nasal delivery device ➤ Subscribe
7,543,581 Nasal devices ➤ Subscribe
7,740,014 Nasal devices ➤ Subscribe
7,841,337 Breath-actuated nasal delivery device ➤ Subscribe
9,119,932 Nasal delivery device ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for XHANCE

Supplementary Protection Certificates for XHANCE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
269 Luxembourg ➤ Subscribe PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C0067 France ➤ Subscribe PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
C0014 France ➤ Subscribe PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
C/GB08/026 United Kingdom ➤ Subscribe PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo
Moodys
Dow
Citi
Novartis
Argus Health
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot